Renerva
Pittsburgh, US · Founded 2017 · Delaware LLC
Renerva develops surgical products aimed at improving nerve healing and recovery following nerve injury. The company operates in the medical device and biotechnology space focused on nerve repair solutions.
Founders & leadership
LS
Lorenzo SolettiLLC Manager
BN
Bryan N. BrownChief Technology Officer
WA
William A SekkelLLC Manager
PD
Peter DeComoLLC Manager
JC
J. Christopher FlahertyExecutive Vice President for Intellectual Property
PA
Paul A GardnerChief Medical Officer
Board
JC
Jonathan CheethamChairman of the Scientific Advisory Board
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 3 rounds · 2018–2025
▶$324.8KraisedSep 2025 · 35 investors · Other Health CareRule 506(b)
▶$324.8KraisedSep 2025 · 35 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peter DeComoDirector
- Bryan N. BrownExecutive Officer
- William A SekkelDirector
- Lorenzo SolettiExecutive Officer, Director, Promoter
- Offering amount
- $1.5M
- Amount sold
- $324.8K
- Proceeds to insiders
- $53K
- First sale
- Sep 2025
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$335KraisedAug 2024 · 14 investors · Other Health CareRule 506(b)
▶$335KraisedAug 2024 · 14 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Lorenzo SolettiExecutive Officer, Director
- Bryan N. BrownExecutive Officer
- William A SekkelDirector
- Peter DeComoDirector
- Offering amount
- $1.5M
- Amount sold
- $335K
- Proceeds to insiders
- $75K
- First sale
- Jul 2024
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$617.3KraisedAug 2018 · 12 investors · Other Health CareRule 506(b)
▶$617.3KraisedAug 2018 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- J. Christopher FlahertyExecutive Officer
- Bryan N. BrownExecutive Officer
- Lorenzo SolettiExecutive Officer, Director
- Paul A GardnerExecutive Officer
- Jonathan CheethamExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $617.3K
- Minimum investment
- $25K
- Proceeds to insiders
- $200K
- First sale
- Jun 2018
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapMinerva Biotechnologies14 shared keywordsMinerva Biotechnologies develops cancer and stem cell therapeutics, including cancer immunotherapies aimed at solid tumors and preventing cancer metastasis. The company also works on patient-derived stem cells for regenerative medicine.
Minerva Neurosciences14 shared keywordsMinerva Neurosciences is a clinical-stage biopharmaceutical company developing product candidates for central nervous system disorders. It focuses on designing clinical trials with endpoints tied to patient benefit.
Minerva Surgical12 shared keywordsMinerva Surgical is a women's health medical device company focused on technologies for conditions such as heavy menstrual bleeding, offering alternatives to hysterectomy. It provides support to clinical teams using its products.
LeadIQ7 shared keywordsLeadIQ offers a company search tool that provides B2B company profiles with data such as revenue, employee count, funding, and contact information to help sales teams find decision makers and build pipeline.
Companies competing with Renerva for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $495K |
| National Science Foundation | Phase II | 2022 | $996.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $274.3K |
| National Science Foundation | Phase I | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Renerva do?
- Renerva develops surgical products aimed at improving nerve healing and recovery following nerve injury. The company operates in the medical device and biotechnology space focused on nerve repair solutions.
- How much funding has Renerva raised?
- Renerva has disclosed $1.3M raised across 3 rounds.
- Where is Renerva headquartered?
- Renerva is headquartered in Pittsburgh, US.